Cowen reissued their average rating on shares of NuCana (NASDAQ:NCNA) in a research note issued to investors on Wednesday morning, AnalystRatings.com reports.
A number of other equities analysts also recently commented on the company. Piper Sandler reiterated an overweight rating and set a $15.00 price objective on shares of NuCana in a research report on Wednesday. HC Wainwright reiterated a buy rating and set a $16.00 price objective on shares of NuCana in a research report on Tuesday, May 19th. Finally, Oppenheimer assumed coverage on NuCana in a research report on Thursday, July 23rd. They set an outperform rating and a $20.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $16.25.
NASDAQ NCNA opened at $5.55 on Wednesday. The company has a market cap of $180.26 million, a PE ratio of -7.03 and a beta of 1.09. The stock’s 50 day simple moving average is $5.50 and its 200-day simple moving average is $5.59. NuCana has a 1-year low of $3.81 and a 1-year high of $10.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.19 and a quick ratio of 10.19.
NuCana (NASDAQ:NCNA) last released its earnings results on Tuesday, May 19th. The company reported ($12.00) earnings per share for the quarter, beating the consensus estimate of ($18.20) by $6.20. On average, equities research analysts anticipate that NuCana will post -0.76 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of NCNA. Sigma Planning Corp purchased a new stake in NuCana in the first quarter valued at $65,000. Geode Capital Management LLC purchased a new stake in NuCana in the fourth quarter valued at $75,000. Wedbush Securities Inc. purchased a new stake in NuCana in the second quarter valued at $88,000. Blair William & Co. IL raised its position in NuCana by 18.0% in the first quarter. Blair William & Co. IL now owns 19,625 shares of the company’s stock valued at $114,000 after purchasing an additional 3,000 shares during the period. Finally, Marshall Wace LLP raised its position in NuCana by 380.0% in the fourth quarter. Marshall Wace LLP now owns 65,784 shares of the company’s stock valued at $401,000 after purchasing an additional 52,079 shares during the period. Institutional investors own 41.41% of the company’s stock.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer.
See Also: Systematic Risk
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.